Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in KIT-mutated Melanoma
NCT00788775Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in mucosal melanoma (MM), acral lentiginous melanoma (ALM), melanoma, sponsored by Dana-Farber Cancer Institute. Started Jan 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
mucosal melanoma (MM)acral lentiginous melanoma (ALM)melanoma
Beyond the preview
Go deeper on NCT00788775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788775.